WO2004091494A3 - Method for preparation of site-specific protein conjugates - Google Patents

Method for preparation of site-specific protein conjugates Download PDF

Info

Publication number
WO2004091494A3
WO2004091494A3 PCT/US2004/010995 US2004010995W WO2004091494A3 WO 2004091494 A3 WO2004091494 A3 WO 2004091494A3 US 2004010995 W US2004010995 W US 2004010995W WO 2004091494 A3 WO2004091494 A3 WO 2004091494A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
site
conjugate
protein
preparation
Prior art date
Application number
PCT/US2004/010995
Other languages
French (fr)
Other versions
WO2004091494A2 (en
Inventor
Kenneth Hinds
Danny Lewis
Paul Schmidt
Kathleen M Campbell
Original Assignee
Pr Pharmaceuticals Inc
Kenneth Hinds
Danny Lewis
Paul Schmidt
Kathleen M Campbell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pr Pharmaceuticals Inc, Kenneth Hinds, Danny Lewis, Paul Schmidt, Kathleen M Campbell filed Critical Pr Pharmaceuticals Inc
Priority to EP04759347.0A priority Critical patent/EP1613272B1/en
Priority to US10/553,570 priority patent/US9040664B2/en
Priority to CA2521381A priority patent/CA2521381C/en
Priority to AU2004229461A priority patent/AU2004229461A1/en
Priority to BR122016021907A priority patent/BR122016021907B8/en
Priority to BRPI0409322A priority patent/BRPI0409322B8/en
Priority to JP2006509863A priority patent/JP2006522816A/en
Publication of WO2004091494A2 publication Critical patent/WO2004091494A2/en
Publication of WO2004091494A3 publication Critical patent/WO2004091494A3/en
Priority to AU2010212312A priority patent/AU2010212312B2/en
Priority to US14/691,855 priority patent/US9789196B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Abstract

The invention is directed to a single-step method for rapidly and efficiently preparing protein-polymer conjugates, including an insulin-polymer conjugate. According to the method of the present invention, a protein and hydrophilic polymer are contacted in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the protein and polymer. Thus, the invention is directed to the site-specific modification of selected proteins, such as insulin, with poly(ethylene glycol) at residue PheB 1. The invention also provides a pharmaceutical formulation for encapsulating the conjugate in a biodegradable polymer.
PCT/US2004/010995 2003-04-11 2004-04-08 Method for preparation of site-specific protein conjugates WO2004091494A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP04759347.0A EP1613272B1 (en) 2003-04-11 2004-04-08 Method for preparation of site-specific protein conjugates
US10/553,570 US9040664B2 (en) 2003-04-11 2004-04-08 Materials and methods for preparing protein-polymer conjugates
CA2521381A CA2521381C (en) 2003-04-11 2004-04-08 Method for preparation of site-specific protein conjugates
AU2004229461A AU2004229461A1 (en) 2003-04-11 2004-04-08 Method for preparation of site-specific protein conjugates
BR122016021907A BR122016021907B8 (en) 2003-04-11 2004-04-08 insulin-peg conjugate, poly(lactideco-glycolide) microsphere, drug release formulation, and usage
BRPI0409322A BRPI0409322B8 (en) 2003-04-11 2004-04-08 method for preparing an insulin-polymer conjugate
JP2006509863A JP2006522816A (en) 2003-04-11 2004-04-08 Method for preparing site-specific protein conjugates
AU2010212312A AU2010212312B2 (en) 2003-04-11 2010-08-12 Method for preparation of site-specific protein conjugates
US14/691,855 US9789196B2 (en) 2003-04-11 2015-04-21 Site-specific insulin-polymer conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46236403P 2003-04-11 2003-04-11
US60/462,364 2003-04-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10/553,570 A-371-Of-International US9040664B2 (en) 2003-04-11 2004-04-08 Materials and methods for preparing protein-polymer conjugates
US14/691,855 Division US9789196B2 (en) 2003-04-11 2015-04-21 Site-specific insulin-polymer conjugates

Publications (2)

Publication Number Publication Date
WO2004091494A2 WO2004091494A2 (en) 2004-10-28
WO2004091494A3 true WO2004091494A3 (en) 2006-02-09

Family

ID=33299938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/010995 WO2004091494A2 (en) 2003-04-11 2004-04-08 Method for preparation of site-specific protein conjugates

Country Status (9)

Country Link
US (2) US9040664B2 (en)
EP (2) EP2599502B1 (en)
JP (3) JP2006522816A (en)
CN (2) CN101514223B (en)
AU (2) AU2004229461A1 (en)
BR (2) BRPI0409322B8 (en)
CA (2) CA3074393A1 (en)
DK (1) DK2599502T3 (en)
WO (1) WO2004091494A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590235B2 (en) 2013-09-08 2023-02-28 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2427092T3 (en) 2003-04-10 2013-10-28 Evonik Corporation A method for the production of emulsion-based microparticles
AU2004229461A1 (en) * 2003-04-11 2004-10-28 Pr Pharmaceuticals Inc. Method for preparation of site-specific protein conjugates
CA2532302C (en) 2003-07-15 2016-12-20 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
BRPI0412211A (en) 2003-07-23 2006-08-22 Pr Pharmaceuticals Inc controlled release compositions
SI1648933T1 (en) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Long lasting insulin derivatives and methods thereof
WO2005039641A2 (en) * 2003-10-15 2005-05-06 The Regents Of The University Of California Biomacromolecule polymer conjugates
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
JP5528710B2 (en) * 2006-02-28 2014-06-25 オリガシス コーポレイション Polymer conjugate containing acryloyloxyethyl phosphorylcholine and process for producing the same
US8394921B2 (en) * 2006-07-25 2013-03-12 Lipoxen Technologies Limited N-terminal derivatisation of proteins with polysaccharides
CA2659990C (en) * 2006-08-04 2016-03-22 Prolong Pharmaceuticals, Inc. Polyethylene glycol erythropoietin conjugates
TWI451876B (en) 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
WO2010030366A2 (en) 2008-09-11 2010-03-18 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CN102369209B (en) * 2009-03-20 2015-06-10 韩美科学株式会社 Method for preparing a site-specific physiologically active polypeptide conjugate
GB0905555D0 (en) * 2009-03-31 2009-05-13 Peptcell Ltd Pharmaceutical agent
IN2012DN00407A (en) 2009-08-05 2015-08-21 Pieris Ag
TW201138831A (en) * 2009-09-30 2011-11-16 Prolong Pharmaceuticals Inc Modified granulocyte colony stimulating factor (G-CSF)
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
AR081066A1 (en) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
KR20130049671A (en) * 2011-11-04 2013-05-14 한미사이언스 주식회사 Method for preparation of biological active polypeptide conjugate
AR090281A1 (en) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
AR090843A1 (en) 2012-05-09 2014-12-10 Lilly Co Eli TREATMENT FOR DIABETES COMORBID WITH CHRONIC RENAL DISEASE
WO2014029012A1 (en) * 2012-08-23 2014-02-27 Stemcell Technologies Inc. Compositions and methods for rapid and reversible biomolecular labeling
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US9439864B2 (en) * 2014-07-07 2016-09-13 Antriabio, Inc. Solvent extraction from biodegradable microparticles
JP2017525370A (en) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing and using tumor necrosis factor superfamily and TNF-like ligand muteins
KR20210013299A (en) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 Butyrylcholinesterase zwitterionic polymer conjugates
US20160151511A1 (en) * 2014-12-02 2016-06-02 Antriabio, Inc. Proteins and protein conjugates with increased hydrophobicity
WO2016196017A1 (en) 2015-06-04 2016-12-08 Antriabio, Inc. Amine pegylation methods for the preparation of site-specific protein conjugates
RU2744860C2 (en) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Antibodies and their conjugates
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930542A1 (en) * 1979-07-27 1981-02-12 Hoechst Ag NEW INSULINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
US5102872A (en) 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1998046212A1 (en) 1997-04-17 1998-10-22 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
CN1284603C (en) 1999-10-08 2006-11-15 内科塔治疗亚拉巴马公司 Heterobifunctional poly(ethylene Glycol) derivatives and methods for their preparation
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CN1507357A (en) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ Method and compositions for enhanced delivery of bioactive molecules
CA2429254A1 (en) 2000-11-20 2002-05-30 James M. Dunn Oral nanosphere delivery
CN1314445C (en) * 2001-05-21 2007-05-09 耐科塔医药公司 Pulmonary administration of chemically modified insulin
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
AU2004229461A1 (en) * 2003-04-11 2004-10-28 Pr Pharmaceuticals Inc. Method for preparation of site-specific protein conjugates
GB201107664D0 (en) 2011-05-09 2011-06-22 Univ Leuven Kath Sensor for detecting liquid spilling

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HINDS ET AL.: "PEGy;ated insulin in PGLA microparticels. In vivo and in vitro analysis.", JOURNAL OF CONTROL RELEASE, vol. 104, April 2005 (2005-04-01), pages 447 - 460, XP004903358 *
See also references of EP1613272A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590235B2 (en) 2013-09-08 2023-02-28 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates

Also Published As

Publication number Publication date
BRPI0409322B8 (en) 2021-05-25
AU2010212312A1 (en) 2010-09-02
CA3074393A1 (en) 2004-10-28
EP1613272A2 (en) 2006-01-11
WO2004091494A2 (en) 2004-10-28
US9040664B2 (en) 2015-05-26
BR122016021907B8 (en) 2021-07-27
CN101514223B (en) 2017-03-01
BR122016021907B1 (en) 2018-01-09
CA2521381C (en) 2020-05-26
EP2599502A2 (en) 2013-06-05
JP2010248241A (en) 2010-11-04
CA2521381A1 (en) 2004-10-28
EP1613272B1 (en) 2013-12-18
US20150216995A1 (en) 2015-08-06
US9789196B2 (en) 2017-10-17
EP2599502A3 (en) 2014-07-30
JP5576200B2 (en) 2014-08-20
EP2599502B1 (en) 2017-03-01
BRPI0409322A (en) 2006-04-25
EP1613272A4 (en) 2010-06-16
AU2010212312B2 (en) 2012-05-17
US20070083006A1 (en) 2007-04-12
AU2004229461A1 (en) 2004-10-28
DK2599502T3 (en) 2017-04-18
CN1777440A (en) 2006-05-24
CN101514223A (en) 2009-08-26
JP2006522816A (en) 2006-10-05
BRPI0409322B1 (en) 2017-02-07
JP2013256498A (en) 2013-12-26

Similar Documents

Publication Publication Date Title
WO2004091494A3 (en) Method for preparation of site-specific protein conjugates
WO2004030617A3 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
Zhang et al. Dynamic covalent polymers for biomedical applications
WO2001045796A3 (en) Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
CN101588819B (en) Factor ix moiety-polymer conjugates having a releaseable linkage
ES2833035T3 (en) Biodegradable water insoluble hydrogels based on polyethylene glycol
WO2001051510A3 (en) G-csf conjugates
WO2002077036A3 (en) Recombinant production of polyanionic polymers, and uses thereof
DE60012010D1 (en) HYPERBRANCHED DENDRITIC POLYETHER AND ITS PRODUCTION PROCESS
BR9808933A (en) Composition in the form of microcapsules or implants, process for the preparation of a water-soluble substance, active substance, triptorelin acetate, lanreotide acetate, or octreotide acetate, and double-stranded rna
DK1968638T3 (en) Controlled release gels
CY1110169T1 (en) METHOD OF MANUFACTURING POLYMER WITH SPECIFIC ACTIVE GROUPS FROM POLYMER ALCOHOLS
WO2008081014A3 (en) Process for manufacturing vaccines
WO2006065951A3 (en) Sustained delivery formulations of octreotide compounds
WO2003000777A3 (en) Multi-arm block copolymers as drug delivery vehicles
Lee et al. PEGylation to improve protein stability during melt processing
ATE312129T1 (en) MODIFIED POST-CONDENSED POLYESTER
AU2002364625A1 (en) Pharmaceutical compositions in the form of gel or solution based on dihydrotestosterone, preparation method and uses thereof
WO2005029076A3 (en) Nanoparticle conjugates and method of production thereof
DE60222734D1 (en) Microparticles and process for their preparation
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
BR0015596A (en) Method of preparing particles of a substance, and, particles of a substance
EP2241309A3 (en) Methods for encapsulation of proteins and adjuants in microspheres
Andrianov Water-soluble polyphosphazenes for biomedical applications
WO2006102659A3 (en) CONJUGATES OF AN hGH MOIETY AND A POLYMER

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004229461

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2521381

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006509863

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004229461

Country of ref document: AU

Date of ref document: 20040408

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004229461

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048097228

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2004759347

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2960/CHENP/2005

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004759347

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0409322

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2007083006

Country of ref document: US

Ref document number: 10553570

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10553570

Country of ref document: US